ERBB2 and breast cancer: Also, in this case, the Luminal A subtype was more represented among Group BC+EN+ patients (73.3% vs. 38.3%), while the Luminal B HER2+ subtype was more represented among Group BC+EN− patients (28.3% vs. 6.7%).